AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00588406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium bromide
Description: 2.5 mg, one dose
Study NCT00588406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60mg PO
Study NCT00588406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 60mg PO
Study NCT03814369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmplifEYE
Description: AmplifEYE colonoscopy
Study NCT00369928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dose
Description: placebo, BID, oral for 12 weeks
Study NCT00369928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: 25 mg BID, of oral PG-760564
Study NCT04276831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope McCoy
Description: Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
Study NCT04276831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope Macintosh
Description: Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
Study NCT02971072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subacromial injection
Description: A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
Study NCT02971072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: A standardized six-week exercise protocol supervised by a physical therapist
Study NCT01549028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile-based PR program.
Description: Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
Study NCT04950933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huolingshengji Granules
Description: 1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;
Study NCT04950933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole tablet
Description: Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.
Study NCT01636453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent assisted coiling with the Liberty Stent
Description: Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
Study NCT01680991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Multiple doses of obinutuzumab.
Study NCT04227119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irrigated ablation catheter
Description: After completion of ablation, the ablation catheter will be serially positioned in the cardiac chambers (either the left or right side of the heart). The stop cock will be turned to the pressure transducer and waveforms will be stored corresponding to each chamber.
Study NCT04227119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon tipped PA catheter
Description: After removal of the irrigated ablation catheter, a 5F balloon tipped PA catheter which will be positioned under fluoroscopic guidance in each previously evaluated chamber and the chambers will be measured again.
Study NCT03677544 — intervention group
Intervention type: OTHER
Intervention: laparoscopic approach with an extended pelvic lymph
Description: Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
Study NCT03353441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microencapsulated Sublingual Glycine (MSG)
Description: Glycine (MSG) tablet
Study NCT03353441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose tablet manufactured to mimic Glycine (MSG) tablet
Study NCT04602013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Body weight \<60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle
Study NCT04602013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)
Study NCT04602013 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
Study NCT03401216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY 48 mm
Description: Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)
Study NCT03401216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Standard PCI procedure
Study NCT03401216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 month OCT follow-up
Description: Optical coherence tomography imaging of target vessel within 3 month after PCI
Study NCT03401216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 month OCT follow-up
Description: Optical coherence tomography imaging of target vessel within 5 month after PCI
Study NCT02177786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selonsertib
Description: Tablets administered orally once daily
Study NCT02177786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match selonsertib
Description: Tablets administered orally once daily
Study NCT01758172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Study NCT01758172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Study NCT03875872 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
Study NCT03875872 — intervention group
Intervention type: DRUG
Intervention: inhalation anaesthetics
Description: Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
Study NCT02306941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
Study NCT01402323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: time point of tooth extraction
Study NCT03771066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bisphenol A
Description: Vanilla wafer cookie with bisphenol A administered
Study NCT03771066 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vanilla wafer cookie with no bisphenol A
Study NCT02138162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: oral
Study NCT01808365 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior pharyngeal swab
Description: Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
Study NCT01808365 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
Study NCT00003992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00003992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00003992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00003992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Study NCT01940549 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Trauma Focused Therapy + tDCS
Study NCT01940549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Focused Therapy + tDCS
Study NCT00505544 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires that ask about your sleep, symptoms, and mood.
Study NCT00505544 — intervention group
Intervention type: DEVICE
Intervention: Actigraph
Description: Wear actigraph to collect information on activity levels and sleep patterns for one week.
Study NCT02813434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: florbetapir
Description: 18F-AV-45 or 18F-Florbetapir
Study NCT00784459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Treatment with abatacept, 10 mg/kg IV, for 5 doses.
Study NCT00784459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with Placebo, IV
Study NCT01957215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Topical indomethacin
Study NCT01957215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch
Study NCT01875666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg IV, single dose
Study NCT01875666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pertuzumab
Description: 840 mg IV single dose
Study NCT01875666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: 1000 mg daily for 7 days
Study NCT04532281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Murine CD19 CAR-T cells
Description: Each subject receive murine CD19 CAR T-cells by intravenous infusion
Study NCT04513106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP programme Have a Say
Description: It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
Study NCT04513106 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-control health talks
Description: Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants
Study NCT02668328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Theory Tailored Behavioral Intervention
Description: The intervention will enhance self-efficacy
Study NCT04493489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Trial group: BCG + propranolol: after TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
Study NCT04493489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BCG
Description: Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
Study NCT04493489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG
Description: Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
Study NCT02788851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine
Description: Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
Study NCT02788851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
Study NCT02788851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
Study NCT02064829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
Study NCT02064829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IG-001
Description: 260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
Study NCT02613338 — intervention group
Intervention type: DEVICE
Intervention: DePuy Attune posterior stabilizing fixed bearing knee system
Description: Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
Study NCT02986425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRIP intervention
Description: The STRIP intervention consists of 9 steps:~1. structured history taking of medication~2. recording medication and diagnoses in STRIPA~3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~5. shared decision-making with the patient with possible adaptation of the recommendation~6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~7. generation of general practioner (GP) report~8. delivery of the report to the patient and to the GP (optional additional direct communication)~9. follow-up
Study NCT02986425 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
Study NCT03611946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rZIKV/D4Δ30-713 (Administered at a dose of 10^3 plaque-forming units (PFUs) by subcutaneous injection)
Description: Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection
Study NCT03611946 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection.
Study NCT03611946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection.
Study NCT03611946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rZIKV/D4Δ30-713 (Administered at a dose of using 10^4 plaque-forming units (PFUs) by subcutaneous injection).
Description: Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.
Study NCT03600220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: antihypertension drug, acupuncture twice a week for 3 months
Study NCT03083964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
Study NCT03083964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming
Description: The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
Study NCT00520091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT- 11
Description: 65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Study NCT00520091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT- 11
Description: 65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Study NCT00520091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
Study NCT00520091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
Study NCT00520091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
Study NCT00520091 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
Study NCT00520091 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
Study NCT00520091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
Study NCT00520091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
Study NCT01335438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless (Nexgen)
Description: Cementless fixation of Nexgen CR TKR
Study NCT01335438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented (Nexgen)
Description: Cemented fixation of Nexgen CR TKR
Study NCT01172561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Health Advisor Education Intervention
Description: The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
Study NCT01172561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.